Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigehisa Kitano

Showing results (121-130 of 150) with videos related to

Pageof 15
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|August 23, 2017
Metabolic activity by <sup>18</sup>F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLCKyoichi Kaira, Tetsuya Higuchi, Ichiro Naruse, et al.
International Cancer Conference Journal|January 27, 2026
Acute esophageal mucosal injury during pembrolizumab treatment after a hypopharyngeal cancer patient's free jejunal autograft reconstruction, as an immune-related adverse eventYuten Shuri, Kenji Nakano, Koichi Takeda, et al.
Cancer Science|October 23, 2024
FOXP3+/CD8+ ratio associated with aggressive behavior in RUNX3-methylated diffuse esophagogastric junction tumorSuguru Maruyama, Yu Imamura, Tasuku Toihata, et al.
Cancer Immunology Research|May 20, 2016
Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer PatientsKohei Tada, Shigehisa Kitano, Hirokazu Shoji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2022
Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid TumorsJun Sato, Toshio Shimizu, Takafumi Koyama, et al.
International Journal of Hematology|March 25, 2025
Oral beclomethasone dipropionate therapy and prognostic plasma biomarkers for gastrointestinal graft-versus-host diseaseYoshihiro Inamoto, Ayumu Ito, Toshihisa Nakashima, et al.
Vaccine|September 19, 2009
Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432Masatoshi Aoki, Shugo Ueda, Hiroyoshi Nishikawa, et al.
Cancer Immunology Research|January 14, 2014
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitorMargaret K Callahan, Gregg Masters, Christine A Pratilas, et al.
Therapeutic Advances in Medical Oncology|September 15, 2025
Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: a collaborative study of a phase Ib trial of dual HER2 and PD-1 targeted therapy (Ni-High)Hiroki Osumi, Takeru Wakatsuki, Akira Ooki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulanShigehisa Kitano, Shinichi Kageyama, Yasuhiro Nagata, et al.
Pageof 15

Showing results (121-130 of 150) with videos related to

Sort By:
Pageof 15
European Journal of Nuclear Medicine and Molecular Imaging|August 23, 2017
Metabolic activity by <sup>18</sup>F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLCKyoichi Kaira, Tetsuya Higuchi, Ichiro Naruse, et al.
International Cancer Conference Journal|January 27, 2026
Acute esophageal mucosal injury during pembrolizumab treatment after a hypopharyngeal cancer patient's free jejunal autograft reconstruction, as an immune-related adverse eventYuten Shuri, Kenji Nakano, Koichi Takeda, et al.
Cancer Science|October 23, 2024
FOXP3+/CD8+ ratio associated with aggressive behavior in RUNX3-methylated diffuse esophagogastric junction tumorSuguru Maruyama, Yu Imamura, Tasuku Toihata, et al.
Cancer Immunology Research|May 20, 2016
Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer PatientsKohei Tada, Shigehisa Kitano, Hirokazu Shoji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2022
Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid TumorsJun Sato, Toshio Shimizu, Takafumi Koyama, et al.
International Journal of Hematology|March 25, 2025
Oral beclomethasone dipropionate therapy and prognostic plasma biomarkers for gastrointestinal graft-versus-host diseaseYoshihiro Inamoto, Ayumu Ito, Toshihisa Nakashima, et al.
Vaccine|September 19, 2009
Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432Masatoshi Aoki, Shugo Ueda, Hiroyoshi Nishikawa, et al.
Cancer Immunology Research|January 14, 2014
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitorMargaret K Callahan, Gregg Masters, Christine A Pratilas, et al.
Therapeutic Advances in Medical Oncology|September 15, 2025
Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: a collaborative study of a phase Ib trial of dual HER2 and PD-1 targeted therapy (Ni-High)Hiroki Osumi, Takeru Wakatsuki, Akira Ooki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulanShigehisa Kitano, Shinichi Kageyama, Yasuhiro Nagata, et al.
Pageof 15